Role of Bruton's tyrosine kinase in B cells and malignancies
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
A Andrades, P Peinado, JC Alvarez-Perez… - Molecular cancer, 2023 - Springer
Hematological malignancies are a highly heterogeneous group of diseases with varied
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
Abstract Background Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have
transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic …
transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic …
A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
GW Wright, JD Phelan, ZA Coulibaly, S Roulland… - Cancer cell, 2020 - cell.com
The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is
a clinically and genetically heterogeneous disease that is further classified into …
a clinically and genetically heterogeneous disease that is further classified into …
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
The multiple myeloma (MM) genome is heterogeneous and evolves through preclinical and
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7 …
YH Huang, K Cai, PP Xu, L Wang, CX Huang… - … and Targeted Therapy, 2021 - nature.com
Epigenetic alterations play an important role in tumor progression of diffuse large B-cell
lymphoma (DLBCL). However, the biological relevance of epigenetic gene mutations on …
lymphoma (DLBCL). However, the biological relevance of epigenetic gene mutations on …
Germinal center‐derived lymphomas: The darkest side of humoral immunity
One of the unusual features of germinal center (GC) B cells is that they manifest many
hallmarks of cancer cells. Accordingly, most B‐cell neoplasms originate from the GC …
hallmarks of cancer cells. Accordingly, most B‐cell neoplasms originate from the GC …
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets
K Karube, A Enjuanes, I Dlouhy, P Jares… - Leukemia, 2018 - nature.com
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of
somatic mutations and structural alterations. However, the clinical significance of these …
somatic mutations and structural alterations. However, the clinical significance of these …
CXCR4 in Waldenström's Macroglobulinema: chances and challenges
It is one of the major aims in cancer research to improve our understanding of the underlying
mechanisms which initiate and maintain tumor growth and to translate these findings into …
mechanisms which initiate and maintain tumor growth and to translate these findings into …